Northwind Pharmaceuticals, Physician Dispensing

Millennium Research Group Study: US Markets for Physician Dispensing in 2014

Millennium-Research-Group-Study-US-Markets-for-Physician-Dispensing-in-2014-300x198When it comes to in-house dispensing, it’s always good to have an idea of the market in your area. Millennium Research Group recently released a study on the U.S. markets for physician-dispensed cosmeceuticals in 2014.

The analysis included several areas of cosmeceutical products:

  • Anti-aging products
  • Acne treatment products
  • Sun protection products
  • Preparation cosmeceuticals
  • Hydrating moisturizers
  • Chemical Peels

In their analysis, the researchers determined that the market for cosmeceuticals is strong and will continue at a fast pace, especially with anti-aging products, the largest segment by far. Anti-aging products include anti-wrinkle and pigment correcting cosmeceuticals.

To read more about the analysis click here.

At Northwind Pharmaceuticals, we hold the value that the more you know, the greater your chance of success. We are your partner for all things pharmaceutical, providing you with the most accurate and up-to-date information. Our solutions pave the way for simplicity with in-house dispensing and lead you to a better 2015. Contact us today to learn more.

Schedule a free claims analysis now.

Let’s Talk now

Leader in AI-driven health benefits navigation Healthee partners with Northwind

Katherine Lurk | Mar 28th, 2025
A game-changer for employers looking to cut costs and gain control With healthcare costs continuing to rise, employers are seeking new ways to rein in spending without sacrificing the quality of benefits. This partnership enables Healthee clients to optimize prescription drug management, reducing costs through preferable generic drug pricing, high-touch chronic care programs, and more. … more »

continue reading

Healthcare Storm 2025: What Will It Be?

Phillip Berry | Jan 1st, 2025
When it comes to American healthcare, we’ve become really good at highlighting its failings. Watching the flurry of lamentations, frustrations, denigrations, and prognostications, over the last few weeks, would lead any rational person to believe that nothing is working in our healthcare system. And, not only is it “not working,” many people conclude that it … more »

continue reading

New Drugs to Market – October Update

Phillip Berry | Oct 25th, 2024
The Food and Drug Administration (FDA) approved three novel drug therapies in October. One of those therapies,  Hympavzi (marstacimab-hncq), is a medication indicated for the treatment of patients with Hemophilia A and Hemophilia B. Hympavzi utilizes a new pathway to help reduce the risk of bleeding episodes in patients with Hemophilia, a disease that impacts … more »

continue reading